PMID: 7037153Mar 1, 1982Paper

Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy

Cancer
J H GlickJ M Bennett

Abstract

Twenty-five patients with Stage III and IV nodular histiocytic lymphoma (NH), entered on three different Eastern Cooperative Oncology Group protocols from 1972-78, were analyzed for response and survival. A complete response (CR) rate of 44% was observed, with 40% partial responders (PR). Four of the 11 CRs are continuing in their original remission. Median survival for CRs was 52 months; for PRs it was 30 months. The six patients treated with cyclophosphamide-prednisone had a median survival of 18 months versus 51 months for the 19 patients treated with more aggressive combination chemotherapy programs. No significant difference in survival was noted between those patients with both nodular and diffuse histology and those with a pure nodular pattern. The median survival of the 25 NH patients was 47 months and is similar to a group of 101 patients with nodular mixed lymphoma (NM) entered on the same ECOG protocols during this time. This survival is intermediate between the nodular lymphocytic poorly differentiated subtype and diffuse histiocytic lymphoma. It suggests that patients with NH histologies be treated with aggressive combination chemotherapy programs designed to achieve complete remission and prolonged disease-free su...Continue Reading

References

Oct 1, 1974·Cancer·A S PatchefskyW S Hoch

❮ Previous
Next ❯

Citations

Jan 1, 1990·Hematological Oncology·S RehnB Tribukait
Apr 1, 1984·International Journal of Radiation Oncology, Biology, Physics·M K GospodarowiczT Chua
Jan 1, 1986·Critical Reviews in Oncology/hematology·L A MatisD L Longo
Mar 1, 1984·European Journal of Cancer & Clinical Oncology·H P Honegger, F Cavalli
Jan 1, 1985·Hematological Oncology·S H LevittG Frizzera
Nov 1, 1987·Current Problems in Cancer·R T Hoppe
Oct 23, 1997·Hematology/oncology Clinics of North America·T P MillerR I Fisher
Jun 4, 2005·Blood·Michele Ghielmini, Oreste Mora
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K GantiJ O Armitage
Dec 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J OvermanL E Fayad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.